Toronto, Ontario--(Newsfile Corp. - April 16, 2021) - Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the "Company" or "Datametrex") is pleased to announce that it has implemented a new COVID-19 testing program for all the Company employees, consultants, technicians, nurses, and lab partner employees.
Datametrex is implementing this testing protocol with both rapid testing with results in ten (10) minutes, and traditional lab-based polymerase chain reaction ("PCR") testing within twenty-four (24) hours. The manufacturers have confirmed that these tests can determine the new variants which is key as we navigate the third wave and the variants that spreading at a fast pace globally.
Unfortunately, with the increase in transmissible occurring with both the Brazil and UK variants, management felt it was prudent to increase the levels of testing to keep individuals in the Company and community safe from contracting and inadvertently spreading the coronavirus. Everyone in the Company has also received training to monitor compliance to stop the spread of the coronavirus by wearing masks and including 2+2 movement restriction by keeping a distance of 2 metres from others whenever possible.
The testing will be managed by the Company's own trained nurses and processed by our lab partner technicians.
"The new Brazil and UK variants are highly contagious and spreading, management felt a significant need to improve the frequency and level of participation in providing COVID-19 testing for everyone in and around the company as part of the answer to keep people safe," said Marshall Gunter, Chief Executive Officer, Datametrex AI Limited.
Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex's mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain.
For additional information on Datametrex and other corporate information, please visit the Company's website at www.datametrex.com.
For further information, please contact:
Marshall Gunter - CEO
Phone: (514) 295-2300
Neither the TSX Venture Exchange nor it's Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
All statements included in this press release that address activities, events, or developments that the Company expects, believes, or anticipates will or may occur in the future are forward-looking statements. These forward-looking statements involve numerous assumptions made by the Company based on its experience, perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. In addition, these statements involve substantial known and unknown risks and uncertainties that contribute to the possibility that the predictions, forecasts, projections, and other forward-looking statements will prove inaccurate, certain of which are beyond the Company's control. In particular, there is no guarantee that the parties will successfully negotiate and enter into a definitive agreement on mutually acceptable terms or complete the Transaction in the manner contemplated herein, if at all, that the due diligence of any of the parties will be satisfactory, or that the parties will obtain any required board, shareholder, third-party and/or regulatory or other governmental approvals, if any. Readers should not place undue reliance on forward-looking statements. Except as required by law, the Company does not undertake to revise or update these forward-looking statements after the date hereof or revise them to reflect the occurrence of future unanticipated events.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/80610